Trogenix Secures £70 Million Series A to Accelerate Next-Generation Cancer Gene Therapies

Edinburgh-based biotech firm Trogenix Ltd has secured a significant £70 million (approximately US $95 million) Series A financing round to accelerate its pipeline of potentially curative therapies for highly aggressive and treatment-resistant solid tumours.

Founded in 2023 as a spin-out from the University of Edinburgh, Trogenix was incubated by founding investor 4BIO Capital alongside co-founders including Steve Pollard. The company leverages its proprietary Odysseus® platform, which uses Synthetic Super-Enhancers (SSEs) delivered via AAV vectors to home in on cancer-specific cell states and deliver dual therapeutic payloads. This technology enables a two-pronged attack on tumours: selective tumour cell destruction combined with activation of the immune system.

The Series A financing round was led by IQ Capital, with participation from returning backers Cancer Research Horizons (a subsidiary of Cancer Research UK), the Brain Tumour Investment Fund, and new investors including Eli Lilly and Company, Meltwind, LongeVC, and Calculus Capital. Trogenix noted that this investment marks the largest single-company commitment to date by Cancer Research Horizons.

According to CEO Ken Macnamara, the newly secured capital will fast-track the company’s lead programme targeting glioblastoma (GBM) and a follow-on programme in colorectal cancer liver metastases, while also advancing preclinical efforts in hepatocellular carcinoma and non-small-cell lung cancer. The company expects to begin dosing its first patient in the GBM programme in the first quarter of 2026.

Industry observers have pointed out that the size of this financing round places Trogenix among the largest early-stage biotech raises in Europe this year. It reflects a growing investor appetite for transformative “one-and-done” platform technologies that have the potential to cure rather than manage diseases through chronic treatment.

The company’s Synthetic Super-Enhancer approach is central to its therapeutic model. SSEs are engineered DNA elements that function as precise “docking stations” for transcription factors uniquely active in specific cancer cell states. When delivered to tumour cells via viral vectors, these enhancers enable highly selective gene activation. One therapeutic payload converts an inert prodrug into a tumour-killing toxin inside the cancer cell, while a second payload triggers expression of a cytokine to attract and activate immune cells. The resulting “Trojan Horse” effect is designed to eradicate cancerous tissue while leaving healthy cells untouched.

Trogenix’s scientific foundations trace back to the University of Edinburgh’s UK Centre for Mammalian Synthetic Biology and the Institute for Regeneration and Repair, as well as the Cancer Research UK Scotland Centre. The company was founded under the guidance of 4BIO Capital, a venture firm that specialises in early-stage investments in advanced therapies and emerging modalities. Since its inception, Trogenix has quickly drawn the attention of global investors, owing to its potential to redefine treatment paradigms for solid tumours long considered intractable.

This substantial investment will allow Trogenix to expand its laboratory and manufacturing footprint in Edinburgh, grow its clinical development team, and initiate key collaborations with leading oncology research institutions across Europe and North America. The company’s leadership believes the Odysseus® platform could open the door to new categories of targeted viral immunotherapies that combine precision gene delivery with the body’s innate defences.

With clinical milestones on the horizon and a robust investor syndicate that spans pharmaceutical, venture, and research sectors, Trogenix is now positioned to transition from preclinical proof of concept to first-in-human trials. Its progress will be closely watched by both the biotech investment community and oncology researchers seeking new answers for the most lethal forms of cancer.

The successful Series A marks a critical inflection point for the company — one that could see Trogenix emerge as a leader in next-generation cancer gene therapy and a potential flagship for Scotland’s growing life-sciences ecosystem.